

COLON DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: ROSETTI
 SATURDAY APRIL 28, 2018, 7:45 AM – 09:00 AM

CO-CHAIRS : DR. DEREK JONKER & DR. SHARLENE GILL
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to malignancies of the colon.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group relevant to malignancies of the colon.
- To interpret and apply new clinical trial methodologies in the field of clinical research in malignancies of the colon

7:45 am	Setting Strategic Plan	Dr. D. Jonker / Dr. S. Gill
	Active/Recently Closed Trials for Update	
8:15 am	CO.21 (CHALLENGE): A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival In Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (Challenge)	Dr. C. Booth
8:20 am	CO.27: A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for high Risk Stage III Colon Cancer in Adjuvant Setting	Dr. S. Gill
	Approved Trials in Development	
8:30 am	NRG GI1643: Phase II/III study of circulating tumor DNA as a predictive marker for response to adjuvant chemotherapy in patients with stage II colon cancer	Dr. D. Jonker
	New Concepts in Development	
8:40 am	NRG GI004 / SWOG 1610: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Dr. S. Gill
8:50 am	SWOG 1613 –Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Dr. J. Loree
9:00 am	Meeting Adjourned	